Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy

Akkiprik, Mustafa; Koca, Sinan; Uğurlu, M. Ümit; Ekren, Rüçhan; Eyüboğlu, İrem Peker; Alan, Özkan; Erzik, Can; Amuran, Gökçe Gūllū; Telli, Tuğba Akın; Güllüoğlu, M. Bahadır; Sezerman, Uğur; Yumuk, Perran Fulden

doi:10.1016/j.clbc.2020.02.006

Cited by 6 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li S et al reported that lncRNA NEAT1 promotes the BRCA progression by binding miR-146b-5p [46], completely contrary to the results of this study. Meanwhile, Akkiprik M et al reported that miR-146b-5p is upregulated in the peripheral blood of patients with locally advanced BRCA [47], consistent with the results of this study, but the function of miR-146b-5p in cancers needs be more explored in the near future. Thus, this study confirmed that MEG3 could serve as a ceRNA involved in the potential mechanism to positively modulate SLFN5 expression through miR-146b-5p, thereby affecting EMT and invasion capability in BRCA cells (Figure 5).…”

Section: Discussionsupporting

confidence: 90%

The Long Noncoding RNA MEG3 Retains Epithelial-Mesenchymal Transition by Sponging miR-146b-5p to Regulate SLFN5 Expression in Breast Cancer Cells

Zuo

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

More and more studies have shown that long noncoding RNAs (lncRNAs) play essential roles in malignant tumors. The lncRNA MEG3 serves as a crucial molecule in breast cancer development, but the specific molecular mechanism needs to be further explored. We previously reported that Schlafen family member 5 (SLFN5) inhibits breast cancer malignant development by regulating epithelial-mesenchymal transition (EMT), invasion, and proliferation/apoptosis. Herein, we demonstrated that MEG3 was downregulated in pan-cancers and correlated with SLFN5 expression positively in breast cancer by bioinformatics analysis of TCGA and UCSC Xena data. Intervention with MEG3 positively affected SLFN5 expression in breast cancer cells. MEG3 repressed EMT and migration/invasion, similar to our previously reported functions of SLFN5 in breast cancer. Through bioinformatics analysis of starBase and LncBase data, 12 miRNAs were found to regulate both SLFN5 and MEG3, in which miR-146b-5p was confirmed to be regulated by MEG3 using MEG3 siRNA and overexpression method. MiR-146b-5p could bind to both SLFN5 3 ′ UTR and MEG3, and inhibit their expression in a competing endogenous RNA mechanism, assayed by luciferase reporter and RNA pull down methods. Therefore, we conclude that MEG3 positively modulates SLFN5 expression by sponging miR-146b-5p and inhibits breast cancer development.

show abstract

Section: Discussionsupporting

confidence: 90%

The Long Noncoding RNA MEG3 Retains Epithelial-Mesenchymal Transition by Sponging miR-146b-5p to Regulate SLFN5 Expression in Breast Cancer Cells

Zuo

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…From secondary analyses done on a cohort of 48 post-operative patients recruited in the frame of the SUCCESS A trial, miR-127 correlated with the presence of CTCs ( 108 ). Some miRNAs, particularly miR-199a-5p, have been shown to predict CTC clearance during treatment in patients with locally advanced BC exposed to neoadjuvant treatment, providing a molecular response assessment ( 109 ).…”

Section: Circulating Tumor Rnas (Ctrnas)mentioning

confidence: 99%

Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer

Nicolò,

Gianni,

Pontolillo

et al. 2024

Transl Breast Cancer Res

View full text Add to dashboard Cite

Liquid biopsy has emerged as a crucial tool in managing breast cancer (BC) patients, offering a minimally invasive approach to detect circulating tumor biomarkers. Until recently, the majority of the studies in BC focused on evaluating a single liquid biopsy analyte, primarily circulating tumor DNA and circulating tumor cells (CTCs). Despite the proven prognostic and predictive value of CTCs, their low abundance when detected using enrichment methods, especially in the early stages, poses a significant challenge. It is becoming evident that combining diverse circulating biomarkers, each representing different facets of tumor biology, has the potential to enhance the management of patients with BC. This article emphasizes the importance of considering these biomarkers as complementary/synergistic rather than competitive, recognizing their ability to contribute to a comprehensive disease profile. The review provides an overview of the clinical significance of simultaneously analyzing CTCs and other biomarkers, including cell-free circulating DNA, extracellular vesicles, non-canonical CTCs, cell-free RNAs, and non-malignant cells. Such a comprehensive liquid biopsy approach holds promise not only in BC but also in other cancer types, offering opportunities for early detection, prognostication, and therapy monitoring. However, addressing associated challenges, such as refining detection methods and establishing standardized protocols, is crucial for realizing the full potential of liquid biopsy in transforming our understanding and approach to BC. As the field evolves, collaborative efforts will be instrumental in unlocking the revolutionary impact of liquid biopsy in BC research and management.

show abstract

“…It has been demonstrated that a higher number of CTCs increases the risk of BC metastasis and reduces the survival rates of patients [ 97 ]. Akkiprik et al [ 54 ] investigated the potential of differential expression profiles of miRNAs and CTCs in predicting the response and early recurrence of locally advanced BC in blood plasma samples extracted before and after NAT. Interestingly, authors found a six-fold decrease ( p = 0.008) in miR-146b-5p expression in CTC+ patients compared to CTC− patients before treatment.…”

Section: Circulating Mirnas As Indicators Of Clinical Response To Nat...mentioning

confidence: 99%

Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer

Ruiz-Manriquez,

Villarreal-Garza,

Benavides-Aguilar

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is a leading cause of cancer-related deaths among women worldwide. Neoadjuvant therapy (NAT) is increasingly being used to reduce tumor burden prior to surgical resection. However, current techniques for assessing tumor response have significant limitations. Additionally, drug resistance is commonly observed, raising a need to identify biomarkers that can predict treatment sensitivity and survival outcomes. Circulating microRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and have been shown to play a significant role in cancer progression as tumor inducers or suppressors. The expression of circulating miRNAs has been found to be significantly altered in breast cancer patients. Moreover, recent studies have suggested that circulating miRNAs can serve as non-invasive biomarkers for predicting response to NAT. Therefore, this review provides a brief overview of recent studies that have demonstrated the potential of circulating miRNAs as biomarkers for predicting the clinical response to NAT in BC patients. The findings of this review will strengthen future research on developing miRNA-based biomarkers and their translation into medical practice, which could significantly improve the clinical management of BC patients undergoing NAT.

show abstract

Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy

Cited by 6 publications

References 48 publications

The Long Noncoding RNA MEG3 Retains Epithelial-Mesenchymal Transition by Sponging miR-146b-5p to Regulate SLFN5 Expression in Breast Cancer Cells

The Long Noncoding RNA MEG3 Retains Epithelial-Mesenchymal Transition by Sponging miR-146b-5p to Regulate SLFN5 Expression in Breast Cancer Cells

Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer

Exploring the Potential Role of Circulating microRNAs as Biomarkers for Predicting Clinical Response to Neoadjuvant Therapy in Breast Cancer

Contact Info

Product

Resources

About